HER2-Targeted Therapies Could Benefit Lung Cancer Patients With HER2 Mutations

A new study shows that drugs targeting HER2 might provide good results in the rare non-small-cell lung cancer (NSCLC) patients with HER2 mutations.
Source: Cancer Network - Category: Cancer & Oncology Source Type: news